Large study finds that people who received the ‘recombinant’ vaccine for the viral condition had a lower risk of cardiovascular problems.

Large study finds that people who received the ‘recombinant’ vaccine for the viral condition had a lower risk of cardiovascular problems.

Natural experiment took advantage of U.S. switch from Zostavax to Shingrix